New Drug Approval

Sofosbuvir, velpatasvir and voxilaprevir

Date of Approval: July 18, 2017

Treatment for: ***Chronic Hepatitis C***

Vosevi (sofosbuvir, velpatasvir and voxilaprevir or SOF/VEL/VOX) is a fixed-dose combination of a nucleotide analogue NS5B polymerase inhibitor (SOF), a pangenotypic NS5A inhibitor (VEL), and a pangenotypic NS3/4A protease inhibitor (VOX) for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.

Neratinib

Date of Approval: July 17, 2017

Treatment for: **Breast Cancer -- Adjuvant**

Company: Puma Biotechnology, Inc.

The U.S. Food and Drug Administration (FDA) has approved Nerlynx (neratinib), a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy.

Guselkumab

Date of Approval: July 13, 2017

Treatment for: **Plaque Psoriasis**

The U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab), an interleukin-23 blocker for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

L-glutamine

Date of Approval: July 7, 2017

Treatment for: **Sickle Cell Anemia**

Endari (L-glutamine) is orally-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling and other complications of sickle cell anemia.

Triptorelin

Date of Approval: June 29, 2017

Treatment for: **Precocious Puberty**

Triptodur (triptorelin) is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients with central precocious puberty.

Betrixaban

Date of Approval: June 23, 2017

Treatment for: **Prevention of Venous Thromboembolism**

Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized for an acute medical illness.

C1 esterase inhibitor (human) Subcutaneous Injection

Date of Approval: June 22, 2017

Treatment for: **Hereditary Angioedema**

Haegarda (C1 esterase inhibitor (human)) is a low-volume subcutaneous (SC) C1-esterase inhibitor (C1-INH) replacement therapy to prevent Hereditary Angioedema (HAE) attacks.

Rituximab and hyaluronidase

Date of Approval: June 22, 2017

Treatment for: **Follicular Lymphoma; Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia**

Rituxan Hycela (rituximab and hyaluronidase human) is a subcutaneous monoclonal antibody and hyaluronidase human formulation for the treatment of adult patients with follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

Delafloxacin

Date of Approval: June 19, 2017

Treatment for: **Skin and Structure Infection**

Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

Source: drugs.com

Information collected and compiled by:
Mr. Md. Akbar Hossain
Assistant Professor
Department of Pharmacy
ASA University, Dhaka